Palbociclib is the first Food and Drug Administration (FDA)-approved CDK4/6 inhibitor with the capacity to improve progression-free survival of breast cancer patients in combination with fulvestrant or letrozole [8,9,10]. This evidence concerns the gene CDK4 and breast cancer.